Floatz logo

MELPHALAN

Childhood Neoplasm

City of Hope Medical CenterSmall moleculePhase 2/3Dormant
BBB
72/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
60/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Childhood Neoplasm cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
City of Hope Medical Center
Phase 2/3BBB
FILGRASTIM
Barbara Ann Karmanos Cancer Institute
Phase 3BBB
Cyclophosphamide
National Cancer Institute (NCI)
Phase 2/3BBB
Carboplatin
Seoul National University Hospital
Phase 2/3BBB
Thiotepa
Roswell Park Cancer Institute
Phase 2/3BBB

View all 50 →

Same molecule, other indications

MELPHALAN is also rated in:

diffuse large B-cell lymphomaActive
BBB
Indicative · Phase 4
76 / 100
View asset →
myelodysplastic/myeloproliferative neoplasmActive
BBB
Indicative · Phase 2/3
76 / 100
View asset →
cancer of unknown primary siteDormant
BBB
Indicative · Phase 2/3
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →